To switch or not to switch: Should the study of tamoxifen and raloxifene (STAR) trial alter our decision?

Taiwanese Journal of Obstetrics and Gynecology

Volumn 47, Issue 3, 2008, Pages 372-374

  Wang, Peng Hui ^a   Chao, Hsiang Tai ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CLOMIFENE; ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CATARACT; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FRACTURE; GYNECOLOGIC DISEASE; HUMAN; HYSTERECTOMY; MONOTHERAPY; OSTEOPOROSIS; OVARY HYPERSTIMULATION; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; THROMBOEMBOLISM; UTERUS CANCER;

EID: 56849132732     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(08)60149-7     Document Type: Letter

References (19)

1. Yin CS. Tamoxifen: to use or not to use. Taiwan J Obstet Gynecol 2008;47:129-30.
2. Wang PH, Chao HT. A reconsideration of tamoxifen use for breast cancer. Taiwan J Obstet Gynecol 2007;46:93-5.
3. Premkumar A, Venzon DJ, Avila N, et al. Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertil Steril 2007;88:1637-44.
4. Barrett-Connor E, Mosca L, Collins P, et al; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
5. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;148:104-7.
6. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
7. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
8. LaCroix AZ, Burke W. Breast cancer and hormone replacement therapy. Lancet 1997;350:1042-3.
9. Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC. Standard and low-dose hormone therapy for postmenopausal women: focus on the breast. Taiwan J Obstet Gynecol 2007;46: 127-34.
10. Lee WL, Cheng MH, Chao HT, Wang PH. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwani Obstet Gynecol 2008;47:24-31.
11. Vogel VG, Costantino JP, Wickerham DL, et al; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006; 295:2727-41.
12. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51.
13. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
14. Toi M. Long-term outcomes of aromatase inhibition for breast cancer. Lancet Oncol 2008;9:8-10.
15. Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw 2006;4:971-9.
16. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-13.
17. Lewis-Wambi JS, Jordan VC. Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs). Breast Dis 2005-6;24:93-105.
18. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007;8:229-39.
19. Aschenbrenner DS. A new indication for raloxifene. Am J Nurs 2008;108:38.